Treatment for severe COVID-19 with a biomimetic sorbent haemoperfusion device in patients on haemodialysis

Diego Sandoval; Inés Rama; María Quero; Miguel Hueso; Francisco Gómez; Josep M Cruzado

doi:10.1093/ckj/sfab010

Treatment for severe COVID-19 with a biomimetic sorbent haemoperfusion device in patients on haemodialysis

Clin Kidney J. 2021 Jan 18;14(5):1475-1477. doi: 10.1093/ckj/sfab010. eCollection 2021 May.

Authors

Diego Sandoval^{1

2}, Inés Rama^{1

2}, María Quero^{1

2}, Miguel Hueso^{1

2}, Francisco Gómez^{1

2}, Josep M Cruzado^{1

2}

Affiliations

¹ Department of Nephrology, Hemodialysis Unit, Bellvitge University Hospital, Hospitalet de LLobregat, Spain.
² Biomedical Research Institute (IDIBELL), Hospital Duran i Reynals, Barcelona, Spain.

Abstract

Haemodialysis (HD) patients present more morbidity and mortality risk in coronavirus disease 2019 (COVID-19). In patients who may develop severe symptoms, the process called 'viral sepsis' seems to be a crucial mechanism. In those cases, the HD procedure provides an excellent tool to explore the benefit of some extracorporeal therapies. We reported the outcome of four HD patients with severe COVID-19 treated with Seraph^®100 haemoperfusion (HP) device. Three of the four cases presented a good clinical response after HP. In conclusion, the treatment with Seraph^®100 device may be a simultaneous treatment to improve HD patients with severe acute respiratory syndrome coronavirus 2.

Keywords: COVID-19; cytokine storm; haemodialysis; haemoperfusion; sepsis viral.

Publication types

Case Reports